Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs

Sabrina Lyngbye Wendt, Carsten Boye Knudsen, John Bagterp Jørgensen, Henrik Madsen, Ahmad Haidar

Research output: Contribution to conferencePosterResearchpeer-review

362 Downloads (Pure)

Abstract

Zealand Pharma has invented a glucagon analogue, ZP-GA-1, with increased stability in liquid formulation for treatment of hypoglycemia. A pharmacodynamic (PD) model is needed to compare ZP-GA-1 with marketed glucagon. We aim to develop a model of the complex glucose-insulin-glucagon dynamics based on physiology and data.
Original languageEnglish
Publication date2016
Number of pages1
Publication statusPublished - 2016
Event9th International Conference on Advanced Technol​ogies and Treatments for Diabetes (ATTD 2016) - Milan, Italy
Duration: 3 Feb 20166 Feb 2016
Conference number: 9
http://www.attd2016.com/

Conference

Conference9th International Conference on Advanced Technol​ogies and Treatments for Diabetes (ATTD 2016)
Number9
CountryItaly
CityMilan
Period03/02/201606/02/2016
Internet address

Bibliographical note

Poster Id: ATTD-0146

Fingerprint Dive into the research topics of 'Modelling the glucose-insulin-glucagon dynamics after subcutaneous administration of native glucagon and a novel glucagon analogue in dogs'. Together they form a unique fingerprint.

Cite this